News & Events

OGT Named OBN’s Best Medtech Dealmaker

OGT Named OBN’s Best Medtech Dealmaker

Winner for Second Year Running for Acquisition of Cytocell

Oxford and Cambridge, UK – 9 October 2014 – Oxford Gene Technology (OGT), the molecular genetics company, has won the Best Medtech Dealmaker award for the second year in a row at the OBN awards held on Thursday 2 October. The award recognises OGT’s acquisition of Cambridge-based Cytocell Limited (Cytocell), a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer.

The acquisition, which took place in March 2014, allowed OGT to increase its genomic medicine offering by enabling entry into the complementary and rapidly growing market for fluorescence in situ hybridisation (FISH) products. Through leveraging its dedicated sales and support infrastructure, OGT now sells Cytocell products directly in North America, providing enhanced service and promotional capabilities.

By acquiring Cytocell, OGT has been able to combine the two companies’ expertise and reach. In addition, access to Cytocell’s proprietary collection of 34,000 Bacterial Artificial Chromosome (BAC) clones provides a unique source of potential products. OGT is already utilising its expanded resources and cross portfolio synergies to develop and promote a number of new products.

Dr Jon Rees, CEO of OBN commented, “The quality of nominees continues to rise year on year and compiling a shortlist and picking winners gets harder. The award of Best Medtech Dealmaker to Oxford Gene Technology reflects what has been a highly successful move for both OGT and Cytocell. To win this award twice in consecutive years makes a real statement about OGT’s ambition, strong business model and strategy.”

Tim Hall, CFO of OGT said, “The acquisition of Cytocell represents our commitment to becoming a global leader in genomic medicine. We are very grateful to the OBN for recognising the opportunity and the value of the deal. Cytocell’s innovative DNA technology and strong brand has added to our portfolio of class-leading genomic technologies, and we are already seeing the benefits.”

The Cytocell acquisition has significantly increased OGT’s sales of genomic products which grew by over 75% in the year ending 30 September 2014.


Notes to Editors

About Oxford Gene Technology

Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, OGT has helped pioneer the molecular medicine revolution by enabling smarter decision making in human healthcare. With customers in over 30 countries worldwide and ambitious expansion plans, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s CytoSure™ and Genefficiency™ range of microarray and next generation sequencing products and services deliver high-quality, high-throughput genetic analysis, enabling accurate identification of the causative variation underlying genetic disease.

For more information on the Company, please visit our website at

CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures


Issued for and on behalf of Oxford Gene Technology by Instinctif Partners.

To contact the Oxford Gene Technology team at Instinctif Partners, email

back to news


Melanie Toyne-SewellManaging Partner